Standout Papers

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an inter... 2018 2026 2020 2023 294
  1. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study (2018)
    Noopur Raje, Evangelos Terpos et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 52 standout
Sub-graph 1 of 23

Citing Papers

Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
2 intermediate papers

Works of Kamel Laribi being referenced

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
2018 Standout
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
2016

Author Peers

Author Last Decade Papers Cites
Kamel Laribi 589 306 314 585 330 60 1.2k
Silvia Mangiacavalli 920 487 284 659 528 56 1.5k
Ana Balanzategui 481 485 533 452 433 70 1.4k
Miguel Alcoceba 354 446 423 428 315 79 1.2k
Surender Juneja 482 526 531 370 284 84 1.3k
Monia Lunghi 1066 621 346 474 447 60 1.7k
A Broustet 999 342 150 286 231 107 1.4k
Jee Sook Hahn 242 220 490 526 327 57 1.2k
Maurizio Musso 672 229 326 354 195 66 1.3k
Lourdes Escoda 944 507 542 553 648 56 1.6k
G. Pagnucco 567 578 555 475 175 68 1.4k

All Works

Loading papers...

Rankless by CCL
2026